Lineagen, Inc.

Barbara K Zedler

Edwin J C G Van Den Oord

Edward Lenn Murrelle

Jason W Flora

Mark F Leppert

Timothy York

Joseph Louie McClay

Thomas O'Connell

Gaurav S J B Rana

Daniel Adkins

Jeffrey S Edmiston

Bradley Todd Webb

Willie J McKinney

Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions.

Biomarkers of lung function

Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is a serious and growing public health concern. The major environmental risk factor for COPD is cigarette smoking, but the biological mechanisms underlying COPD are not well understood. Herein, proton nuclear magnetic resonance (H-NMR) spectroscopy is used in methods to identify metabolites and biomarkers associated with lung function in COPD.

Metabolomics-based biomarkers for lung function

Growing community of inventors

Richmond, VA, United States of America

Barbara K Zedler